Prospective Cohort of Advanced and Metastatic Non-Small Cell Lung Cancer Patients with EGFR Mutations: Long-Term Survival and Other Outcomes After First Line Osimertinib

Prospective Cohort of Advanced and Metastatic Non-Small Cell Lung Cancer Patients with EGFR Mutations: Long-Term Survival and Other Outcomes After First Line Osimertinib - 1L Osimertinib Prospective Cohort Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042961

Enrollment

100

Registered

2021-01-11

Start date

2021-01-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with Stage IIIB-IV NSCLC with EGFR mutation 2)Age 20 or older at the time of advanced NSCLC diagnosis (specific age may vary according to country-specific guidelines) 3)Treated in the first line with osimertinib between August 2018 and December 2020, according to the label

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
To describe overall survival (OS) . To describe progression-free survival (PFS). To describe treatments and sequencing after treatment on first line osimertinib.	—

Secondary

Measure	Time frame
To describe baseline demographic and clinical characteristics: histology, disease stage at diagnosis, EGFR mutation, brain metastases, smoking status, age, gender, performance status etc. To examine the association between baseline characteristics and OS, PFS.	—

Countries

Japan

Contacts

Public ContactKenji Hamada

IQVIA Solutions Japan K.K. Real World Evidence Solutions/HEOR

khamada@jp.imshealth.com+81-80-4591-3561

Outcome results